These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28647161)

  • 1. DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy.
    Radley A; Tait J; Dillon JF
    Int J Drug Policy; 2017 Sep; 47():126-136. PubMed ID: 28647161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Dillon JF
    BMJ Open; 2018 Dec; 8(12):e021443. PubMed ID: 30552244
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Byrne C; Radley A; Inglis SK; Beer LJZ; Palmer N; Pham MD; Healy B; Doyle JS; Donnan P; Dillon JF
    BMJ Open; 2020 Aug; 10(8):e036501. PubMed ID: 32868356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Directly observed hepatitis C treatment with opioid substitution therapy in community pharmacies: A qualitative study.
    Gunn J; Higgs P
    Res Social Adm Pharm; 2020 Sep; 16(9):1298-1301. PubMed ID: 31003763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.
    Butler K; Day C; Dietze P; Bruno R; Alati R; Burns L
    J Subst Abuse Treat; 2015 Nov; 58():90-4. PubMed ID: 26117080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study.
    Midgard H; Bramness JG; Skurtveit S; Haukeland JW; Dalgard O
    PLoS One; 2016; 11(11):e0166451. PubMed ID: 27846264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
    Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J;
    Int J Drug Policy; 2017 Sep; 47():230-238. PubMed ID: 28633998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
    Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ;
    Int J Drug Policy; 2017 Sep; 47():177-186. PubMed ID: 28624134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics.
    Rance J; Newland J; Hopwood M; Treloar C
    Soc Sci Med; 2012 Jan; 74(2):245-53. PubMed ID: 22133583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: An economic evaluation alongside a pragmatic cluster randomised trial.
    Myring G; Lim AG; Hollingworth W; McLeod H; Beer L; Vickerman P; Hickman M; Radley A; Dillon JF
    J Infect; 2022 Dec; 85(6):676-682. PubMed ID: 36170895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.
    Keats J; Micallef M; Grebely J; Hazelwood S; Everingham H; Shrestha N; Jones T; Bath N; Treloar C; Dore GJ; Dunlop A;
    Int J Drug Policy; 2015 Oct; 26(10):999-1006. PubMed ID: 26275578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial.
    Byrne CJ; Radley A; Inglis SK; Beer L; Palmer N; Duc Pham M; Allardice K; Wang H; Robinson E; Hermansson M; Semizarov D; Healy B; Doyle JS; Dillon JF
    Aliment Pharmacol Ther; 2022 Jun; 55(12):1512-1523. PubMed ID: 35538396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study.
    Alavi M; Grebely J; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ;
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S62-9. PubMed ID: 23884068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network.
    Morris L; Smirnov A; Kvassay A; Leslie E; Kavanagh R; Alexander N; Davey G; Williams O; Gilks C; Najman J
    Int J Drug Policy; 2017 Sep; 47():216-220. PubMed ID: 28666635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A quasi-experimental evaluation of dried blood spot testing through community pharmacies in the Tayside region of Scotland.
    Radley A; Melville K; Tait J; Stephens B; Evans JMM; Dillon JF
    Frontline Gastroenterol; 2017 Jul; 8(3):221-228. PubMed ID: 28839912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection.
    Grebely J; Genoway K; Khara M; Duncan F; Viljoen M; Elliott D; Raffa JD; DeVlaming S; Conway B
    Int J Drug Policy; 2007 Oct; 18(5):437-43. PubMed ID: 17854734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy.
    Sasadeusz JJ; Dore G; Kronborg I; Barton D; Yoshihara M; Weltman M
    Addiction; 2011 May; 106(5):977-84. PubMed ID: 21205057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia.
    Treloar C; Rance J; Bath N; Everingham H; Micallef M; Day C; Hazelwood S; Grebely J; Dore GJ
    Int J Drug Policy; 2015 Oct; 26(10):992-8. PubMed ID: 25697089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
    Grebely J; Mauss S; Brown A; Bronowicki JP; Puoti M; Wyles D; Natha M; Zhu Y; Yang J; Kreter B; Brainard DM; Yun C; Carr V; Dore GJ
    Clin Infect Dis; 2016 Dec; 63(11):1405-1411. PubMed ID: 27553375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.